Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Dateline City:

PRINCETON, N.J.

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers
Squibb Company (NYSE: BMY) today announced new results from the
Phase 3 CheckMate -214 study, showing that therapy with Opdivo
(nivolumab) plus low-dose Yervoy (ipilimumab) continued to
demonstrate long-term survival benefits in patients with previously
untreated advanced or metastatic renal cell carcinoma (RCC).

Language:

English

Contact:

Bristol-Myers Squibb Company Media Inquiries: Eric Van Zanten610-529-6219 [email protected] Investors: Tim Power609-252-7509 [email protected] orBill Szablewski609-252-5894 [email protected]

Ticker Slug:

Ticker: BMY Exchange: NYSE

$BMY announces long-term survival data in metastatic renal cell carcinoma at #GU19. #RCC #KidneyCancer #KCSM

read more

Original Source